Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations Thermo Fisher revenue climbs 22% for 2021, buoyed by product launches and the year’s biggest buyout Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data Unvaccinated 23 times more likely than boosted to be hospitalized during omicron wave Gilead to fork over $1.25B, pay 3% royalty on blockbuster Biktarvy in GSK patent settlement Paragonix's lung transport system completes 4,700-mile, cross-country transplant DOJ recovers over $5B in healthcare fraud settlements, judgments in 2021 Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track Kindbody hits unicorn status with Vios Fertility Institute acquisition, new leadership additions How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals details Medtronic's Hugo surgery robot used in first European procedure Biden revives Cancer Moonshot program to seek 50% drop in cancer death rate by 2047 Featured Story | By Kevin Dunleavy With $5.33 billion in sales in the fourth quarter, which exceeded expectations, Humira reached the elusive $20 billion mark in 2021, the company said in its quarterly sales call. As for the future of the megablockbuster, the company said it would provide 2023 guidance later this year. read more |
| |
|---|
|
|
| How To Take Your Imaging Trials to the Next Level with Automation Thursday, March 3, 2022 | 11:00 AM ET / 8:00 AM PT Join experts from ICON Medical Imaging and Medidata for this in-depth webinar to learn how to maximize automation on your imaging trial and discuss how automation: Improves the quality of your data for regulatory submission, creates efficiencies to accelerate your trial, and leverages integration to reduce manual steps. Register now. |
Top Stories By Andrea Park They say you have to spend money to make money, and that definitely proved true for Thermo Fisher Scientific in 2021. read more By Nick Paul Taylor Strike Novartis from the list of rivals to Incyte’s topical eczema drug Opzelura. After getting a look at early clinical data, Novartis has dumped its topical pan-JAK inhibitor CEE321 over an unfavorable risk-benefit profile. read more By Dave Muoio New Los Angeles County public health surveillance data reaffirm vaccines and boosters' protection against COVID-19, and particularly against severe illness. read more By Eric Sagonowsky GlaxoSmithKline and Gilead Sciences have been duking it out in the HIV arena for years, hoping to get an edge over one another with new launches and head-to-head drug trials. Now, in a Tuesday settlement, the companies are resolving a legal dispute over lucrative patents related to GSK's HIV drug dolutegravir. read more By Conor Hale The high-stakes transplant procedure set a new record for the company’s LUNGguard system, pushing past its intended organ storage time of up to eight hours. read more By Dave Muoio Healthcare settlements and judgements comprised the majority of the over $5.6 billion DOJ recovered in fiscal year 2021. read more By Annalee Armstrong Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Disclosed in the fine print of the pharma giant’s fourth-quarter earnings presentation Tuesday was that two more studies are subject to the hold, bringing the total number of affected trials to seven. read more By Rebecca Torrence Fertility startup Kindbody hit a $1.15 billion valuation with its acquisition of Vios Fertility Institute, a deal that gives the company 13 more clinics, doubling its national footprint. read more By Kevin Dunleavy An SEC filing on UCB's recent acquisition of Zogenix details the negotiations it took to get the deal done and for UCB to win out over two other unnamed players. read more By Andrea Park Surgical teams in Europe just gained a new co-worker. A few months after earning CE mark approval, Medtronic’s robotic-assisted surgery system—dubbed Hugo—has made its European debut. read more By Kyle LaHucik President Joe Biden unveiled his second attempt at a "cancer moonshot" with a renewed program focused on slashing the cancer death rate by more than 50% in the next 25 years. read more |
